Despite different mechanism, the good efficacy of BI-1808 in CTCL provide a promising direction for treatment with such cold tumors by promoting CD8 infiltration and granzyme B production in patients. This evidence concerns the gene CD8A and primary cutaneous T-cell non-Hodgkin lymphoma.